Perspectives | Apellis Pharmaceuticals, Inc.

Skip to main navigation

Loading...

About Us
Our Science
For Patients
- For Patients
- PNH
- Geographic Atrophy
- C3G
- CAD
- Expanded Access
Careers
- Careers
- Opportunities
Investors & Media
Contact Us
Twitter
LinkedIn

Investors & Media

Home / Investors & Media / Perspectives Perspectives

Perspectives

Rare Disease Report

December 6, 2018

Potential Paroxysmal Nocturnal Hemoglobinuria Treatment, APL-2, Shows Positive …

Insider Louisville

December 4, 2018

Apellis shares spike on promising new drug data

BioCentury

November 21, 2018

MANAGEMENT TRACKS: BERGENBIO, ALZAMEND

BioWorld

November 21, 2018

Appointments and advancements

Endpoints

November 21, 2018

Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CE…

Seeking Alpha

November 20, 2018

Apellis Pharmaceuticals appoints Adam Townsend as Chief Commercial Officer

Louisville Business First

November 20, 2018

Apellis hires veteran biotech exec for new C-suite role

Retina News

October 30, 2018

APELLIS BEGINS PHASE 3 TRIALS FOR COMPLEMENT INHIBITION IN GA

Healio

September 16, 2018

OSN’s top news of the week

BioWorld

September 13, 2018

Clinical data for Sept. 12, 2018

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Print Page Email Alerts RSS Feeds Contact IR

© Apellis Pharmaceuticals 2020. |

Privacy Policy

This website is intended for residents of the U.S.